Autophagy in Paediatric Crohn's Disease
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age6-17
SponsorHospices Civils de Lyon
About this trial
Crohn's disease is a multifactorial complex disease resulting in a between microbiota and immune system. Indeed, GWAS (Genome-Wide Association Studies) association study pinpointed polymorphisms as genes susceptibility on more than 200 loci. Among them genes coding for proteins involved in autophagy machinery (i.e: ATG16L1, IRGM et NDP52). Autophagy is a ubiquitous intracellular mechanism mandatory for protein and microorganism recycling.
So far, the role of autophagy in gut inflammation and intestinal homeostasis in Crohn's disease patients is partially understand. Then, investigators plan to evaluate, on native cells, the autophagic flux in pediatric patients suffering of a Crohn's disease compare to controls.
Eligibility criteria
Qualifiers
Age between 6 and 17 inclusive
Patients with a weight > 25 kg at the time of inclusion
Patients with Crohn's disease requiring ileocolonoscopy (diagnosis or follow-up)
Mild to severe Crohn's disease consistent with PCDAI disease activity score
Disqualifiers
Refusal to participate in the protocol
Intercurrent infection
Ongoing antibiotic treatment
Patient involved in another interventional study protocol including an exclusion period still in progress at pre-inclusion
Trial design
Treatments tested in this trial
- Blood samples
- Biopsies
Treatment groups
70 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov